Michael McElhaugh
Chief Executive Officer bei ARBUTUS BIOPHARMA CORPORATION
Vermögen: 3 Mio $ am 31.03.2024
Profil
Mr. Michael J.
McElhaugh is a President & Chief Executive Officer at Arbutus Biopharma, Inc. and a President, Chief Executive Officer, COO & Director at Arbutus Biopharma Corp.
He is on the Board of Directors at Arbutus Biopharma Corp.
Mr. McElhaugh was previously employed as a Director-Business Development by Pharmasset, Inc. and a Director-Hepatitis C Worldwide Commercialization by Bristol Myers Squibb Co. He received his undergraduate degree from St. Joseph's University, a graduate degree from Thomas Jefferson University and an MBA from Johnson Graduate School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 25.03.2024 | 1 325 193 ( 0,74% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Michael McElhaugh
| Unternehmen | Position | Beginn |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Chief Executive Officer | 01.01.2024 |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Executive Officer | 01.01.2024 |
Ehemalige bekannte Positionen von Michael McElhaugh
| Unternehmen | Position | Ende |
|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01.03.2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Founder | - |
Ausbildung von Michael McElhaugh
| Thomas Jefferson University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
